Foghorn Therapeutics (FHTX) Accumulated Expenses: 2020-2025
Historic Accumulated Expenses for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $9.8 million.
- Foghorn Therapeutics' Accumulated Expenses fell 12.45% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 12.45%. This contributed to the annual value of $8.5 million for FY2024, which is 6.34% down from last year.
- As of Q3 2025, Foghorn Therapeutics' Accumulated Expenses stood at $9.8 million, which was up 14.69% from $8.6 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Accumulated Expenses ranged from a high of $11.2 million in Q3 2024 and a low of $5.1 million during Q1 2021.
- For the 3-year period, Foghorn Therapeutics' Accumulated Expenses averaged around $8.4 million, with its median value being $8.6 million (2025).
- Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 57.14% in 2022, then declined by 29.06% in 2024.
- Over the past 5 years, Foghorn Therapeutics' Accumulated Expenses (Quarterly) stood at $9.6 million in 2021, then climbed by 15.05% to $11.0 million in 2022, then dropped by 17.21% to $9.1 million in 2023, then declined by 6.34% to $8.5 million in 2024, then decreased by 12.45% to $9.8 million in 2025.
- Its Accumulated Expenses was $9.8 million in Q3 2025, compared to $8.6 million in Q2 2025 and $6.5 million in Q1 2025.